Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20889066 | 0.92 | KMT2A (0.42) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL15892777 | 0.88 | MAPT (0.40) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL15892823 | 0.88 | MAPT (0.40) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL9504654 | 0.86 | CA1 (0.46) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL9504650 | 0.86 | CA1 (0.46) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL18286505 | 0.84 | MAPT (0.38) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL7136072 | 0.83 | TSHR (0.40) | TSHRCA1CA2CA7CA9 | |
| SCHEMBL15892780 | 0.82 | MAPT (0.41) | TSHRMAPTKMT2ASLC1A1CYP2C19 | |
| SCHEMBL15892817 | 0.82 | RCE1 (0.43) | TSHRTACR1MAPTKMT2AHTT | |
| SCHEMBL18286508 | 0.81 | MAPT (0.41) | TSHRCA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210238124-A1 | ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER | THE GENERAL HOSPITAL CORPORATION (US) | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238124-A1 | ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER | AADAC, ACAT2, AANAT | TSHR 3836/4885CA1 672/4885CA2 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.